Category - Developments

Developments

VivoSim intestinal model combined with AI predicts drug-induced diarrhea without animal testing

VivoSim Labs (NASDAQ: VIVS) has announced the availability of an AI prediction tool leveraging its NAMkind intestinal models to accurately predict the potential of a drug to cause diarrhea in patients, eliminating...

April 28, 2026

Developments

Alto launches Phase 2b trial of ALTO-207 in TRD

Alto Neuroscience (NYSE: ANRO) has initiated its Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study...

April 27, 2026

Developments

FDA grants Immutep ODD for efti in STS

Immutep (NASDAQ: IMMP) has announced that the FDA has granted orphan drug designation (ODD) for eftilagimod alfa (efti) for the treatment of soft tissue sarcoma (STS), a rare cancer with significant unmet medical need...

April 27, 2026

Developments

Clearmind reports positive topline results from CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND) has announced that CMND-100, the company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of alcohol use disorder (AUD), has met the primary endpoint in...

April 27, 2026

Developments

Senseonics launches 365-day implantable CGM for T1/T2 diabetes in Europe

Senseonics Holdings (NASDAQ: SENS) has announced the European launch of the world’s first and only one-year implantable continuous glucose monitoring (CGM) system—Eversense 365—now available to patients with Type 1 and...

April 27, 2026

Developments

Meta-analysis of 17 studies shows no clinically meaningful benefit from anti-amyloid Alzheimer’s drugs

According to the authors of a new Cochrane systemic review which examined data from 17 clinical trials with a total of 20,342 participants, the effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive...

April 16, 2026

Developments

FDA grants Arbutus fast track designation for imdusiran in cHBV

Arbutus Biopharma (NASDAQ: ABUS) has announced that the FDA has granted fast track designation for imdusiran for the treatment of chronic hepatitis B (cHBV). Imdusiran is an RNAi therapeutic specifically designed to...

April 15, 2026

Developments

Stereotaxis to acquire Robocath

Stereotaxis (NYSE: STXS) has announced that it has entered into a definitive agreement to acquire closely held Robocath, a venture-backed innovator of robotic techniques for interventional cardiology and...

April 15, 2026

Developments

MHRA clears Poolbeg for cancer immunotherapy trial

Poolbeg Pharma (AIM: POLB; OTC: POLBF; FRA: POLBF) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the company clinical trial authorization for its TOPICAL trial with...

April 15, 2026

Developments

SIR highlights Profound’s CAPTAIN study results showing faster recovery with TULSA v robotic prostate surgery

The Society of Interventional Radiology (SIR) has highlighted the results of Profound Medical’s (NASDAQ: PROF; TSX: PRN) randomized post-market CAPTAIN trial demonstrating that men with localized, intermediate-risk...

April 14, 2026

Category - Developments

Subscribe